uniQure (NASDAQ:QURE) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of uniQure (NASDAQ:QURE) have been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $31.91.

Several equities research analysts have commented on QURE shares. StockNews.com upgraded uniQure to a “sell” rating in a research note on Friday, March 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $28.00 target price on shares of uniQure in a research report on Tuesday, January 16th. Mizuho cut their price target on shares of uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of uniQure in a research note on Wednesday. Finally, The Goldman Sachs Group downgraded uniQure from a “buy” rating to a “neutral” rating and lowered their target price for the company from $63.00 to $8.00 in a research report on Thursday, February 29th.

uniQure Stock Up 1.5 %

uniQure stock opened at $4.89 on Friday. uniQure has a twelve month low of $4.25 and a twelve month high of $22.48. The company has a quick ratio of 8.68, a current ratio of 8.85 and a debt-to-equity ratio of 0.49. The company has a 50 day moving average of $5.00 and a 200-day moving average of $5.88. The stock has a market capitalization of $233.93 million, a PE ratio of -0.75 and a beta of 0.98.

uniQure (NASDAQ:QURE) last released its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.54) by $0.01. The firm had revenue of $6.69 million during the quarter, compared to analysts’ expectations of $3.20 million. uniQure had a negative return on equity of 99.31% and a negative net margin of 1,947.09%. On average, equities research analysts anticipate that uniQure will post -4.49 EPS for the current fiscal year.

Insider Buying and Selling

In other uniQure news, COO Pierre Caloz sold 9,455 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.47, for a total transaction of $61,173.85. Following the completion of the sale, the chief operating officer now owns 85,643 shares of the company’s stock, valued at approximately $554,110.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Matthew C. Kapusta sold 27,904 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $6.35, for a total value of $177,190.40. Following the transaction, the chief executive officer now owns 440,839 shares of the company’s stock, valued at $2,799,327.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Pierre Caloz sold 9,455 shares of uniQure stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $6.47, for a total value of $61,173.85. Following the sale, the chief operating officer now directly owns 85,643 shares of the company’s stock, valued at $554,110.21. The disclosure for this sale can be found here. In the last three months, insiders have sold 53,265 shares of company stock valued at $339,845. 4.74% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in QURE. Raymond James & Associates grew its stake in shares of uniQure by 6.4% in the fourth quarter. Raymond James & Associates now owns 52,224 shares of the biotechnology company’s stock valued at $354,000 after acquiring an additional 3,145 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of uniQure by 58.5% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 3,664 shares during the period. BluePath Capital Management LLC acquired a new stake in shares of uniQure in the third quarter valued at approximately $27,000. Headlands Technologies LLC acquired a new stake in shares of uniQure in the third quarter valued at approximately $31,000. Finally, Harbor Capital Advisors Inc. boosted its stake in shares of uniQure by 21.1% in the fourth quarter. Harbor Capital Advisors Inc. now owns 30,883 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 5,389 shares during the period. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.